Example of Cancer Chemotherapy and Pharmacology format

Sample paper formatted on SciSpace - SciSpace

This content is only for preview purposes. The original open access content can be found here.

Open Access

Cancer Chemotherapy and Pharmacology — Template for authors

Publisher: Springer

Your data will always be in your control. Learn more

Get started with a free account

— or sign up using email —

See how it works

Guideline source

Categories	Rank	Trend in last 3 yrs
Pharmacology (medical)	#57 of 246	up by 2 ranks
Toxicology	#34 of 122	down by 2 ranks
Pharmacology	#90 of 297	up by 1 rank
Oncology	#104 of 340	up by 1 rank
Cancer Research	#94 of 207	down by 2 ranks

Journal quality:

High

Last 4 years overview: 919 Published Papers | 5067 Citations

Indexed in: Scopus

Last updated: 17/06/2020

Related journals

Insights

General info

Related Journals

Open Access

Recommended

Drug Resistance Updates

Elsevier

Quality:

High

CiteRatio: 20.1

SJR: 4.01

SNIP: 3.079

Open Access

International Journal of Clinical Pharmacy

Springer

Quality:

High

CiteRatio: 2.7

SJR: 0.538

SNIP: 0.974

Open Access

Investigational New Drugs

Springer

Quality:

High

CiteRatio: 5.6

SJR: 1.254

SNIP: 0.855

Open Access

Recommended

Journal for ImmunoTherapy of Cancer

Springer

Quality:

High

CiteRatio: 10.4

SJR: 5.06

SNIP: 2.281

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

2.967

1% from 2018

Impact factor for Cancer Chemotherapy and Pharmacology from 2016 - 2019
Year	Value
2019	2.967
2018	3.008
2017	2.808
2016	2.737

Graph view

5.5

2% from 2019

CiteRatio for Cancer Chemotherapy and Pharmacology from 2016 - 2020
Year	Value
2020	5.5
2019	5.6
2018	5.4
2017	5.3
2016	5.8

Graph view

Insights

Impact factor of this journal has decreased by 1% in last year.
This journal’s impact factor is in the top 10 percentile category.

Insights

CiteRatio of this journal has decreased by 2% in last years.
This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.112

10% from 2019

SJR for Cancer Chemotherapy and Pharmacology from 2016 - 2020
Year	Value
2020	1.112
2019	1.239
2018	1.199
2017	1.147
2016	1.204

Graph view

0.926

11% from 2019

SNIP for Cancer Chemotherapy and Pharmacology from 2016 - 2020
Year	Value
2020	0.926
2019	1.04
2018	0.96
2017	0.906
2016	0.928

Graph view

Insights

SJR of this journal has decreased by 10% in last years.
This journal’s SJR is in the top 10 percentile category.

Insights

SNIP of this journal has decreased by 11% in last years.
This journal’s SNIP is in the top 10 percentile category.

Cancer Chemotherapy and Pharmacology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Cancer Chemotherapy and Pharmacology

Addressing a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels, Cancer Chemotherapy and Pharmacology is an eminent journal in the field. The primary focus in this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. It is essential reading for pharmacologists and oncologists giving results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed or comply with standards equivalent to the UKCCCR guidelines for the welfare of animals in experimental neoplasia (Br J Cancer 58: 109-113, 1988). The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfil the above-mentioned requirements. Read Less

Pharmacology (medical)

Toxicology

Oncology

Cancer Research

Medicine

Last updated on	17 Jun 2020
ISSN	1606-8610
Impact Factor	Medium - 0.965
Acceptance Rate	34%
Open Access	No
Sherpa RoMEO Archiving Policy	White
Plagiarism Check	Available via Turnitin
Endnote Style	Download Available
Bibliography Name	SPBASIC
Citation Type	Author Year (Blonder et al, 1982)
Bibliography Example	Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

Journal Article • DOI: 10.1007/BF00300234 •

Determination of subcutaneous tumor size in athymic (nude) mice

Mary M. Tomayko¹, C. Patrick Reynolds¹ •

01 Jan 1989 - Cancer Chemotherapy and Pharmacology

Abstract:

The athymic (nude) mouse is a useful model for studying the biology and response to therapies of human tumors in vivo. A survey of recent literature revealed the use of 19 different formulas for determining the size of subcutaneous tumors grown as xenografts in nude mice (2 for determining tumor area, 3 for tumor diameter, an... The athymic (nude) mouse is a useful model for studying the biology and response to therapies of human tumors in vivo. A survey of recent literature revealed the use of 19 different formulas for determining the size of subcutaneous tumors grown as xenografts in nude mice (2 for determining tumor area, 3 for tumor diameter, and 14 for calculating tumor volume). We compared the volumes, areas, and diameters predicted by each of the 19 formulas with the actual weights of 50 tumors ranging from 0.46 to 22.0 g established in nude mice as xenografts from human cell lines. In addition to determining how well each formula predicted relative tumor size, we analyzed how well each formula estimated actual tumor mass. The ellipsoid volume formulas (π/6 x L x W x H and 1/2 x L x W x H) were best for estimating tumor mass (r=0.93), whereas measurements of diameter correlated poorly with tumor mass (r<0.66). Although determination of tumor area correlated well with tumor mass in small tumors (r=0.89), correlations of area with tumor mass for large tumors were poor (r=0.41). We conclude that determination of the ellipsoid volume from measurements of three axes consistently yields the most accurate estimations of both relative and actual tumor mass. read more

1,568 Citations

Journal Article • DOI: 10.1007/S002800051097 •

Matrix metalloproteinases and metastasis.

David E. Kleiner¹, William G. Stetler-Stevenson¹ •

01 Jan 1999 - Cancer Chemotherapy and Pharmacology

Abstract:

Metastatic disease is responsible for the majority of cancer-related deaths, either directly due to tumor involvement of critical organs or indirectly due to complications of therapy to control tumor growth and spread. An understanding of the mechanisms of tumor cell invasion and metastasis may be important for devising thera... Metastatic disease is responsible for the majority of cancer-related deaths, either directly due to tumor involvement of critical organs or indirectly due to complications of therapy to control tumor growth and spread. An understanding of the mechanisms of tumor cell invasion and metastasis may be important for devising therapies aimed at preventing tumor cell spread. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteinases whose enzymatic activity is directed against components of the extracellular matrix (ECM). In humans, 16 members of this family have been identified by cloning and sequencing. These proteinases are linked by a core of common domain structures and by their relationship to a family of proteinase inhibitors called the tissue inhibitors of metalloproteinases (TIMPs). Four members of the TIMP family have been cloned and sequenced in humans and they inhibit MMPs by forming tight-binding, noncovalent associations with the active site of the MMPs. MMPs facilitate tumor cell invasion and metastasis by at least three distinct mechanisms. First, proteinase action removes physical barriers to invasion through degradation of ECM macromolecules such as collagens, laminins, and proteoglycans. This has been demonstrated in vitro through the use of chemoinvasion assays and in vivo by the presence of active MMPs at the invasive front of tumors. Second, MMPs have the ability to modulate cell adhesion. For cells to move through the ECM, they must be able to form new cell-matrix and cell-cell attachments and break existing ones. Using a cell transfection system that altered the ratio of MMP-2 to TIMP-2 we have demonstrated significant variation in the adhesive phenotype of tumor cells. Finally, MMPs may act on ECM components or other proteins to uncover hidden biologic activities. For example, the angiogenesis inhibitor angiostatin may be produced from plasminogen by MMP action and laminin-5 is specifically degraded by MMP-2 to produce a soluble chemotactic fragment. Thus MMPs play multiple key roles in facilitating the metastasis of tumor cells. Therapies designed to interfere with specific MMP actions may be useful in the control of metastatic disease. read more

Topics:

Matrix metalloproteinase (55%)55% related to the paper, Extracellular matrix (54%)54% related to the paper, Tumor progression (53%)53% related to the paper,

680 Citations

Journal Article • DOI: 10.1007/S002800050043 •

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Johannes Schüller, Jim Cassidy¹, •

01 Jan 2000 - Cancer Chemotherapy and Pharmacology

Abstract:

Purpose: Capecitabine (Xeloda) is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumors. The purpose of this study was to demonstrate the preferential activation of capecitabine, after oral administration, in tumor in colorectal cancer patients, by the comparison of ... Purpose: Capecitabine (Xeloda) is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumors. The purpose of this study was to demonstrate the preferential activation of capecitabine, after oral administration, in tumor in colorectal cancer patients, by the comparison of 5-FU concentrations in tumor tissues, healthy tissues and plasma. Methods: Nineteen patients requiring surgical resection of primary tumor and/or liver metastases received 1,255 mg/m2 of capecitabine twice daily p.o. for 5–7 days prior to surgery. On the day of surgery, samples of tumor tissue, adjacent healthy tissue and blood samples were collected simultaneously from each patient, 2 to 12 h after the last dose of capecitabine had been administered. Concentrations of 5-FU in various tissues and plasma were determined by HPLC. The activities of the enzymes (CD, TP and DPD) involved in the formation and catabolism of 5-FU were measured in tissue homogenates, by catabolic assays. Results: The ratio of 5-FU concentrations in tumor to adjacent healthy tissue (T/H) was used as the primary marker for the preferential activation of capecitabine in tumor. In primary colorectal tumors, the concentration of 5-FU was on average 3.2 times higher than in adjacent healthy tissue (P=0.002). The mean liver metastasis/healthy tissue 5-FU concentration ratio was 1.4 (P=0.49, not statistically different). The mean tissue/plasma 5-FU concentration ratios exceeded 20 for colorectal tumor and ranged from 8 to 10 for other tissues. Conclusions: The results demonstrated the preferential activation of capecitabine to 5-FU in colorectal tumor, after oral administration to patients. This is explained to a great extent by the activity of TP in colorectal tumor tissue, (the enzyme responsible for the conversion of 5′-DFUR to 5-FU), which is approximately four times that in adjacent healthy tissue. In the liver, TP activity is approximately equal in metastatic and healthy tissue, which explains the lack of preferential activation of capecitabine in these tissues. read more

Topics:

Capecitabine (62%)62% related to the paper, Primary tumor (57%)57% related to the paper, Colorectal cancer (53%)53% related to the paper,

647 Citations

Journal Article • DOI: 10.1007/S00280-016-2976-Z •

Platinum-based drugs: past, present and future.

Shahana Dilruba¹, Ganna V. Kalayda¹ •

17 Feb 2016 - Cancer Chemotherapy and Pharmacology

Abstract:

Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Much effort has been put into the development of new platinum anticancer complexes, but no... Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clinical application so far. Nedaplatin, lobaplatin and heptaplatin received only regional approval. Some new platinum complexes and platinum drug formulations are undergoing clinical trials. Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biologically active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems. For each class of compounds, a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clinically used platinum drugs, and the clinical perspectives are discussed. A critical analysis of lessons to be learned is presented. Finally, a general outlook regarding future directions in the field of new platinum drugs is given. read more

Topics:

Lobaplatin (57%)57% related to the paper, Nedaplatin (52%)52% related to the paper, Carboplatin (51%)51% related to the paper,

570 Citations

Journal Article • DOI: 10.1007/BF00689048 •

Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

Jeffrey G. Supko, Robert L. Hickman,

01 Jan 1995 - Cancer Chemotherapy and Pharmacology

Abstract:

The plasma pharmacokinetics of the antitumor antibiotic geldanamycin (GM; NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 μg/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro, were achieved ... The plasma pharmacokinetics of the antitumor antibiotic geldanamycin (GM; NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 μg/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro, were achieved in the plasma of the mice and the dog treated by i.v. injection. However, the systemic duration of the drug was relatively short. Plasma levels decayed below 0.1 μg/ml within 3–4 h after administration of the apparent maximum tolerated doses, which were approximately 20 mg/kg for the mice and 4 mg/kg for the dog. The drug exhibited linear pharmacokinetic behavior within the dose ranges studied. However, there were significant interspecies differences in its disposition. Whereas the mean biological half-life of GM was slightly longer in the mice (77.7 min) than in the dog (57.9 min), its mean residence time in the dog (46.6 min) was more than twofold greater than that observed in the mice (20.7 min). Nevertheless, the drug was cleared from plasma much faster by the dog (49.4 ml/min per kg) than by the mice (30.5 ml/min per kg). These apparent anomalies were principally associated with differences in the relative significance of the terminal phase upon overall drug disposition. The liver appeared to be the principal target organ of acute drug toxicity in the dog. Doses of 2.0 and 4.2 mg/kg both produced elevations in serum levels of the transaminases and other indicators of liver function characteristic of acute hepatic necrosis. Additional effects included symptoms of minor gastrointestinal toxicity and alterations in serum chemistry parameters consistent with less severe nephrotoxicity. Drug-related toxicity appeared to be reversible. In consideration of the potential for acute hepatotoxic reactions to GM, as well as to the other benzoquinoid ansamycins based upon structural analogy, additional pharmacological and therapeutic information is required to ascertain whether these compounds are viable candidates for clinical development. read more

Topics:

Pharmacokinetics (53%)53% related to the paper, Liver function (53%)53% related to the paper, Neoplastic cell (53%)53% related to the paper,

525 Citations

Also popular among researchers

“

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds

Choose a template

Select a template from a library of 40,000+ templates

Import a MS-Word file or start fresh

It takes only few seconds to import

View and edit your final output

SciSpace will automatically format your output to meet journal guidelines

Submit directly or Download

Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

With SciSpace, you do not need a word template for Cancer Chemotherapy and Pharmacology.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

Easy support from all your favorite tools

Cancer Chemotherapy and Pharmacology format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Cancer Chemotherapy and Pharmacology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Cancer Chemotherapy and Pharmacology guidelines and auto format it.

2. Do you follow the Cancer Chemotherapy and Pharmacology guidelines?

Yes, the template is compliant with the Cancer Chemotherapy and Pharmacology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Cancer Chemotherapy and Pharmacology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Cancer Chemotherapy and Pharmacology citation style.

4. Can I use the Cancer Chemotherapy and Pharmacology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Cancer Chemotherapy and Pharmacology.

5. Can I use a manuscript in Cancer Chemotherapy and Pharmacology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Cancer Chemotherapy and Pharmacology that you can download at the end.

6. How long does it usually take you to format my papers in Cancer Chemotherapy and Pharmacology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Cancer Chemotherapy and Pharmacology.

7. Where can I find the template for the Cancer Chemotherapy and Pharmacology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Cancer Chemotherapy and Pharmacology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Cancer Chemotherapy and Pharmacology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Cancer Chemotherapy and Pharmacology an online tool or is there a desktop version?

SciSpace's Cancer Chemotherapy and Pharmacology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Cancer Chemotherapy and Pharmacology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Cancer Chemotherapy and Pharmacology?”

11. What is the output that I would get after using Cancer Chemotherapy and Pharmacology?

After writing your paper autoformatting in Cancer Chemotherapy and Pharmacology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Cancer Chemotherapy and Pharmacology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Cancer Chemotherapy and Pharmacology?

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Cancer Chemotherapy and Pharmacology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour	Archiving policy
Green	Can archive pre-print and post-print or publisher's version/PDF
Blue	Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow	Can archive pre-print (ie pre-refereeing)
White	Archiving not formally supported

FYI:

Pre-prints as being the version of the paper before peer review and
Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Cancer Chemotherapy and Pharmacology?

The 5 most common citation types in order of usage for Cancer Chemotherapy and Pharmacology are:.

S. No.	Citation Style Type
1.	Author Year
2.	Numbered
3.	Numbered (Superscripted)
4.	Author Year (Cited Pages)
5.	Footnote

15. How do I submit my article to the Cancer Chemotherapy and Pharmacology?

16. Can I download Cancer Chemotherapy and Pharmacology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Cancer Chemotherapy and Pharmacology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Cancer Chemotherapy and Pharmacology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

“

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

”

Andreas Frutiger
Researcher & Ex MS Word user

Cancer Chemotherapy and Pharmacology — Template for authors

Related Journals

Journal Performance & Insights

Impact Factor

CiteRatio

2.967

5.5

Insights

Insights

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

1.112

0.926

Insights

Insights

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology

Top papers written in this journal

Abstract:

Abstract:

Topics:

Abstract:

Topics:

Abstract:

Topics:

Abstract:

Topics:

What to expect from SciSpace?

Speed and accuracy over MS Word

Plagiarism Reports via Turnitin

Freedom from formatting guidelines

Easy support from all your favorite tools

Frequently asked questions

Fast and reliable, built for complaince.

No word template required

Verifed journal formats

Trusted by academicians

Fast and reliable,
built for complaince.